CN116870110A - 一种降尿酸药食同源组方及其制备方法与应用 - Google Patents
一种降尿酸药食同源组方及其制备方法与应用 Download PDFInfo
- Publication number
- CN116870110A CN116870110A CN202310916640.6A CN202310916640A CN116870110A CN 116870110 A CN116870110 A CN 116870110A CN 202310916640 A CN202310916640 A CN 202310916640A CN 116870110 A CN116870110 A CN 116870110A
- Authority
- CN
- China
- Prior art keywords
- parts
- uric acid
- formula
- medicine
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 75
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 74
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 229940116269 uric acid Drugs 0.000 title claims abstract description 72
- 235000013305 food Nutrition 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000009472 formulation Methods 0.000 title claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 21
- 244000197580 Poria cocos Species 0.000 claims abstract description 20
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 20
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 18
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 18
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 18
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 18
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 17
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 17
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 17
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 17
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 17
- 238000001914 filtration Methods 0.000 claims abstract description 17
- 238000010992 reflux Methods 0.000 claims abstract description 16
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 15
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 8
- 230000002829 reductive effect Effects 0.000 claims abstract description 8
- 238000002791 soaking Methods 0.000 claims abstract description 8
- 239000000047 product Substances 0.000 claims abstract description 7
- 238000005303 weighing Methods 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 239000006228 supernatant Substances 0.000 claims abstract description 5
- 230000003907 kidney function Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 39
- 238000009835 boiling Methods 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 4
- 235000008085 high protein diet Nutrition 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000000378 dietary effect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 238000009776 industrial production Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 241000700159 Rattus Species 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 13
- 210000005084 renal tissue Anatomy 0.000 description 9
- 201000005569 Gout Diseases 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940126673 western medicines Drugs 0.000 description 4
- 206010018634 Gouty Arthritis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940089639 cornsilk Drugs 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000001039 kidney glomerulus Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001231 zea mays silk Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降尿酸药食同源组方,包括以下重量份的原料:薏苡仁15‑30份、茯苓10‑20份、车前草8‑15份、山药10‑20份、红花5‑10份和葛根8‑15份;制备方法:(1)称取各原料;(2)混合均匀;(3)加水,浸泡,回流,过滤;(4)再次加水,回流,过滤;(5)合并提取液;(6)浓缩,即得;或,加入乙醇并搅拌,冷藏过夜,过滤,上清液减压浓缩,即得。本发明药食同源组方具有降尿酸、保护肾功能的作用,同时具有组方简单、疗效明显、无毒副作用的特点,且制备简单,操作方便,可用于工业化生产。
Description
技术领域
本发明涉及中药保健技术领域,更具体的说是涉及一种降尿酸药食同源组方及其制备方法与应用。
背景技术
高尿酸血症是嘌呤代谢紊乱引起的代谢异常综合征,是继高血压、高脂血症和高血糖症之后的第四大常见基础代谢疾病。高尿酸血症是痛风性关节炎最重要的生化基础。当体内血尿酸超过其血液或组织液中的饱和度即可在关节局部形成尿酸钠晶体并沉积,继而诱发局部炎性反应和组织破坏,即痛风性关节炎。根据第一财经商业数据中心(CBNData)《2021中国高尿酸血症及痛风趋势白皮书》,近年来,我国高尿酸血症呈明显上升和年轻化趋势,中国高尿酸血症的总体患病率为13.3%,患病人数约为1.77亿,约20%的高尿酸血症会最终发展为痛风,因此治疗痛风病的关键是降尿酸。
虽然西药在降尿酸领域中也取得了显著的成果,但是西药临床应用中常常伴随胃肠道反应、肝肾损伤等不良反应,且在停药后易复发,使得高尿酸血症治疗成为一个难题。我国传统中药应用于高尿酸血症已有较为悠久的历史,中药具有多成分多靶点的特点,不仅能通过抑制尿酸产生相关酶的活性而降低尿酸生成,亦能通过促进尿酸排泄而降低尿酸,大部分应用于高尿酸血症领域的中药还能有效减缓关节炎症的发生;且中药药性温和,在发挥治疗作用时不良反应的发生率明显低于西药,部分中药甚至能够在发挥作用的同时对肾脏具有保护作用,所以中药在解决高尿酸难题上具有潜在的优势。
药食同源植物具有毒副作用小、价格低廉、食用广泛、材料丰富等优势,在治疗高尿酸血症方面具有广阔的前景,正在国外降尿酸功能性食品开发中绽放异彩。目前国内主打降尿酸、防治痛风的产品中菊苣、栀子应用最为广泛,玉米须、桑叶、薏苡仁等也有应用,市面上流通的产品总体表现为配方相似、同质化严重。
由此可见,国内对防治痛风病的药食同源中药的研究十分欠缺,加之逐步扩充的市场需求,药简力宏,配伍考究的药食同源组方的研发是本领域技术人员亟需解决的问题。
发明内容
有鉴于此,本发明的目的在于提供一种降尿酸药食同源组方及其制备方法与应用,以解决现有技术中的不足。
为了实现上述目的,本发明采用如下技术方案:
一种降尿酸药食同源组方,包括以下重量份的原料:薏苡仁15-30份、茯苓10-20份、车前草8-15份、山药10-20份、红花5-10份和葛根8-15份。
优选为:薏苡仁30份、茯苓20份、车前草15份、山药20份、红花10份和葛根15份;
或,薏苡仁20份、茯苓15份、车前草10份、山药15份、红花5份和葛根10份;
或,薏苡仁15份、茯苓10份、车前草8份、山药10份、红花5份和葛根8份。
中医认为高尿酸血症多与“湿邪”相关,为病机关键。湿之来源无外乎内外二因,二者互为因果,合而为病。外湿常指外感六淫之湿邪,多因气候潮湿、涉水淋雨、居处潮湿;内湿多由素体亏虚,嗜欲无节,寒热不调,情志不畅,导致肝脾肾功能失调,水液代谢紊乱。湿郁酿痰化浊生瘀,痰、浊、瘀为其病理产物,同时又成为新的致病因素,蕴结体内,共同为患。由此,湿热是高尿酸血症发病关键,脾虚是发病根本,而基本病机在于脾虚湿阻。
本方用于治疗脾虚湿阻型高尿酸血症,临床表现为关节不痛,周身困倦,头昏头晕,腰膝酸痛,纳食减少,脘腹胀闷,口淡或口粘,舌质淡胖或有齿痕,苔白或黄腻,脉细或弦滑等。
方解:本研究健脾益气以正本,利湿化浊以清源。方中以薏苡仁为君药,既能健脾止泻,又能清热渗湿,还能利关节,舒筋脉。车前草、山药和茯苓共为臣药,茯苓利水渗湿、健脾,与薏苡仁合用,健脾除湿效果尤佳;车前草清热利尿通淋,增强薏苡仁清热利湿之功;山药加强薏苡仁健脾益肾之力,其养阴生津之性还能减少君药、臣药滑泄之性引起的津液耗伤。
佐以葛根,其升脾胃清阳,加强薏苡仁、茯苓、山药健脾之力,脾主升清降浊之力,清阳升于上,浊阴得降,进而加强薏苡仁、茯苓、车前草、红花利湿化浊之功。红花为使药,主逐血瘀,通行血脉。能活血通络,引药周流全身,使气血流通,增强药效。薏苡仁,茯苓,车前草,山药,红花,葛根六药合用,补脾益肾,清热化湿而使气血流通自如。
一种降尿酸药食同源组方的制备方法,具体包括以下步骤:
(1)按上述降尿酸药食同源组方的重量份数称取各原料;
(2)将各原料混合均匀,得到中药混合物;
(3)向中药混合物中加水,浸泡,回流,过滤,分别得到提取液A和药渣A;
(4)向药渣A中再次加水,回流,过滤,分别得到提取液B和药渣B;
(5)将提取液A和提取液B合并,得到混合提取液;
(6)将混合提取液浓缩,即得降尿酸药食同源组方;
或,向混合提取液中加入乙醇并搅拌,冷藏过夜,过滤,将上清液减压浓缩,即得降尿酸药食同源组方。
进一步,上述步骤(3)中,水为蒸馏水,用量为中药混合物体积的6倍;浸泡的时间为30min;回流的状态为微沸,时间为50min。
进一步,上述步骤(4)中,水为蒸馏水,用量为药渣A体积的4倍;回流的状态为微沸,时间为40min。
进一步,上述步骤(6)中,浓缩至1g/mL。
进一步,上述步骤(6)中,乙醇加入至醇浓度到达50%,减压浓缩的温度为70℃,真空度为(-0.09)-(-0.1)MPa。
采用上述进一步技术方案的有益效果在于,本发明组合物中含有较多淀粉,醇沉后降低了的组合物粘稠度,可适用于工业生产中更多的剂型。
本发明还请求保护一种上述降尿酸药食同源组方或如上述制备方法制得的降尿酸药食同源组方在制备降尿酸或治疗由高蛋白饮食引发的肾功能损伤的药物或保健品中的应用。
进一步,上述降尿酸药食同源组方适用于高尿酸时期,包括无症状高尿酸血症时期、急性痛风性关节炎发作时期、尿酸钠沉积于关节的非发作期、痛风石和痛风性肾病时期等。
进一步,上述药物或保健品为片剂、胶囊、袋泡茶和功能饮料等。更进一步,将降尿酸药食同源组方中的各原料粉碎后混匀,按照常规的制备方法制成片剂、胶囊剂、软胶囊、散剂、丸剂和颗粒剂等常规口服剂型;或,按常规的中药提取方法提取降尿酸药食同源组方中各原料的活性组分,再加上食品及药学上可以接受的辅料,按照常规的制备方法制成合适的口服剂型。
经由上述的技术方案可知,与现有技术相比,本发明的有益效果如下:
1、本发明根据卫健委发布的药食同源中药目录,选取薏苡仁,茯苓,车前草,山药,红花,葛根进行科学复配,提供了一种能够降低尿酸的药食同源中药组合物,其具有组方简单、疗效明显、无毒副作用的特点。
2、本发明通过动物实验对其药效进行了确证,动物实验结果表明,本发明药食同源组方具有降尿酸、保护肾功能的作用。
3、本发明降尿酸药食同源组方制备简单,操作方便,可用于工业化生产。
附图说明
图1为对照组与模型组第14天血清尿酸浓度;
图2为重新分组后各组的尿酸浓度;
图3为给药35天后的大鼠体重;
图4为给药35天后的24小时摄水量;
图5为给药35天后的血尿酸浓度;
图6为给药35天后的血尿素氮浓度;
图7为各组对高尿酸血症大鼠肝脏组织病理变化的影响;
图8为各组对高尿酸血症大鼠肾脏组织病理变化的影响。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
以下实施例中,所用薏苡仁,茯苓,车前草,山药,红花,葛根饮片均购自河北安国药材市场,产地分别为贵州、安徽、江西、河南、新疆、河北;所用试验材料如无特殊说明均为自常规生化试剂商店购买得到的;未注明具体条件的实验方法通常按照本领域的公知手段。
实施例1
降尿酸药食同源组方,包括以下重量的原料:薏苡仁30g、茯苓20g、车前草15g、山药20g、红花10g和葛根15g;
上述降尿酸药食同源组方的制备方法,具体包括以下步骤:
(1)按上述降尿酸药食同源组方的重量称取各原料;
(2)将各原料混合均匀,得到中药混合物;
(3)向中药混合物中加入6倍体积的蒸馏水,浸泡30min,微沸状态下回流50min,过滤,分别得到提取液A和药渣A;
(4)向药渣A中再次加入4倍体积的蒸馏水,微沸状态下回流40min,过滤,分别得到提取液B和药渣B;
(5)将提取液A和提取液B合并,得到混合提取液;
(6)将混合提取液浓缩至1g/mL,即得降尿酸药食同源组方。
实施例2
降尿酸药食同源组方,包括以下重量的原料:薏苡仁20g、茯苓15g、车前草10g、山药15g、红花5g和葛根10g;
上述降尿酸药食同源组方的制备方法,具体包括以下步骤:
(1)按上述降尿酸药食同源组方的重量称取各原料;
(2)将各原料混合均匀,得到中药混合物;
(3)向中药混合物中加入6倍体积的蒸馏水,浸泡30min,微沸状态下回流50min,过滤,分别得到提取液A和药渣A;
(4)向药渣A中再次加入4倍体积的蒸馏水,微沸状态下回流40min,过滤,分别得到提取液B和药渣B;
(5)将提取液A和提取液B合并,得到混合提取液;
(6)向混合提取液中加入乙醇并搅拌至醇浓度到达50%,冷藏过夜,过滤,将上清液在温度为70℃、真空度为-0.1MPa的条件下减压浓缩,即得降尿酸药食同源组方。
实施例3
降尿酸药食同源组方,包括以下重量的原料:薏苡仁15g、茯苓10g、车前草8g、山药10g、红花5g和葛根8g;
上述降尿酸药食同源组方的制备方法,具体包括以下步骤:
(1)按上述降尿酸药食同源组方的重量称取各原料;
(2)将各原料混合均匀,得到中药混合物;
(3)向中药混合物中加入6倍体积的蒸馏水,浸泡30min,微沸状态下回流50min,过滤,分别得到提取液A和药渣A;
(4)向药渣A中再次加入4倍体积的蒸馏水,微沸状态下回流40min,过滤,分别得到提取液B和药渣B;
(5)将提取液A和提取液B合并,得到混合提取液;
(6)向混合提取液中加入乙醇并搅拌至醇浓度到达50%,冷藏过夜,过滤,将上清液在温度为70℃、真空度为-0.09MPa的条件下减压浓缩,即得降尿酸药食同源组方。
性能测试
取实施例1制得的降尿酸药食同源组方(简称“实施例1组方”),确证其改善酵母膏、氧嗪酸钾诱导的大鼠高尿酸血症的作用。
a)实验动物
6周龄雄性SD大鼠,体重180~200g,从斯贝福(北京)生物技术有限公司购入。大鼠于中国医学科学院药用植物研究所动物房[SYXK(京)2023-0008]分笼饲养,每笼6只,温度22~25℃,明暗周期12h/12h,所有动物均可自由获得水和食物。
b)动物分组与给药
SD大鼠适应性喂养1周后,按体重随机分为对照组和模型组,模型组再分为模型对照组(对应图2-8中的“模型组”)、阳性药组、实施例1组方中剂量组和实施例1组方高剂量组,每组6只,每天记录体重。以实施例1组方的处方量(薏苡仁30g,茯苓20g,车前草15g,山药20g,红花10g,葛根15g)为每日推荐给药剂量,实施例1组方中剂量组和实施例1组方高剂量组分别为2倍、4倍推荐给药剂量。根据成人给中药组方药量的换算,确定各组剂量。
每天早上同一时间模型组灌胃酵母膏(15g/kg)和氧嗪酸钾(200mg/kg),对照组灌胃等体积无菌水,连续给药14天。第15天开始,早上给药后,每天下午同一时间阳性药组、实施例1组方中剂量组和实施例1组方高剂量组分别灌胃给予10mg/kg别嘌醇片、22.69g/kg实施例1组方和45.38g/kg实施例1组方,对照组和模型对照组灌胃等体积无菌水,连续给药21天。
c)动物样本的收集
动物血清的收集
造模第14天,灌胃酵母膏和氧嗪酸钾1h后,各组大鼠尾静脉采血约200μL。室温下放置1h,4000rpm,4℃条件下离心10min,获得血清。
实验第35天,所有大鼠给药1h后,麻醉,腹主动脉取血于5mL真空采集管中,室温下放置1h,4000rpm,4℃条件下离心10min,移液枪吸取上层血清分装于1.5mL离心管中,于-80℃冰箱保存。
动物脏器组织的收集
实验第35天,取血完成后,在冰盒上快速分离大鼠的脑、心、肝、脾、肺、肾、睾丸,生理盐水润洗后用滤纸吸干表面,称重记录脏器重量并计算脏器系数。称重后,迅速将小块肝和肾组织分别放入固定液中固定。
d)实验指标的测定方法
尿酸、尿素氮水平的测定
按照试剂盒说明书,采用酶比色法测定血清尿酸(Sur)水平,采用脲酶法测定血清尿素氮(BUN)水平。
e)数据计算公式与处理软件
数据采用平均值±标准差的形式表示。使用单因素方差分析(one-way ANOVA)对数据进行处理,结果用Mean±SD表示。选用One-wayANOVA结合Unpairedttest方法进行组间差异分析。P值小于0.05表示统计学差异显著性,作图用GraphPadPrism9.0,其中“*”,“#”分别表示与对照组、模型组存在显著性差异。
f)酵母膏和氧嗪酸钾联合喂养大鼠高尿酸血症的建立
对照组与模型组第14天血清尿酸浓度如图1所示。
由图1可知,经过14天的连续给药,对照组的血尿酸浓度为112.0μmol/L,模型组的血尿酸浓度为153.2μmol/L,两组血尿酸值存在显著性差异(**,unpairedttest,P<0.01),说明高尿酸模型构建成功。
根据尿酸值,重新调整了分组,重新分组后各组的尿酸浓度如图2所示。
由图2可知,重新分组后的各组均与对照组存在显著性差异,而各组间无显著性差异,可以开始给药。
g)实施例1组方对酵母膏和氧嗪酸钾联合喂养大鼠的影响
给药35天后的大鼠体重如图3所示,给药35天后的24小时摄水量如图4所示。
由图3和图4可知,与对照组相比,模型组体重和摄水量显著降低(P<0.05)。给药期间,阳性药组和实施例1组方高剂量组摄水量明显高于模型组(P<0.01)。
给药35天后的血尿酸浓度如图5所示。
由图5可知,连续给予造模剂35天后,模型组的血尿酸值显著高于对照(P<0.05),进一步确证了模型的构建成功。阳性药组和实施例1组方中剂量组均可以显著降低血尿酸浓度,实施例1组方高剂量组也有降低血尿酸的作用,但效果弱于实施例1组方中剂量组,与模型组不存在显著性差异。阳性药组效果过盛,甚至远低于对照组。
给药35天后的血尿素氮浓度如图6所示。
由图6可知,模型组的血尿素氮相比对照组明显升高(p<0.001),可能是因为外源性的蛋白质摄入的过多,超过了大鼠机体的代谢能力,也可能是造模剂引起了肾损伤,需要结合肾脏组织切片进行分析。阳性药组相比模型组更加显著增加了血尿素氮的含量,说明阳性药可能引起了肾脏损伤,需要结合肾脏组织切片进行分析。而实施例1组方中剂量组(p<0.01)和实施例1组方高剂量组(p<0.01)均能显著逆转血尿素氮的升高。
各组对高尿酸血症大鼠肝脏组织病理变化的影响(HE染色,×200)如图7所示(A.对照组;B.模型组;C.阳性药组;D.实施例1组方中剂量组;E.实施例1组方高剂量组)。
由图7可知,与空白组相比,模型组肝组织局部可见较多肝细胞水样变性,组织边缘可见多处肝细胞坏死,核固缩深染(黄色箭头);阳性药组核固缩深染或溶解(黄色箭头),实施例1组方中剂量组的大鼠肝组织内未见明显的病理性改变,实施例1组方高剂量组大鼠有轻微胞质疏松淡染(黑色箭头)。由此可见,肝组织切片中模型组和阳性药组均可见肝细胞变性,阳性药组最重,实施例1组方中剂量组和实施例1组方高剂量组均能减轻肝组织的损伤,其中实施例1组方中剂量组的效果更好。
各组对高尿酸血症大鼠肾脏组织病理变化的影响(HE染色,×400)如图8所示(A.对照组;B.模型组;C.阳性药组;D.实施例1组方中剂量组;E.实施例1组方高剂量组)。
由图8可知,与空白组相比,模型组肾小球内有炎症细胞浸润且系膜细胞少量增生(黑色箭头),肾小管细胞炎症细胞浸润(黄色箭头),近曲小管上皮细胞出现脱落现象(蓝色箭头);阳性药组肾小球内有肾间质的水肿(黑色箭头),肾小管细胞炎症细胞浸润(黄色箭头),近曲小管上皮细胞出现脱落现象(蓝色箭头);实施例1组方中剂量组和实施例1组方高剂量组的大鼠肾组织切片均未见明显的病理性改变。由此可见,肾脏组织切片中模型组和阳性药组均可见明显的肾脏损伤,模型组较重,实施例1组方中剂量组和实施例1组方高剂量组均能有效减轻肾脏组织的损伤,两各剂量组的效果无明显差异。
以上研究结果表明,本发明实施例1降尿酸药食同源组方可以有效降低酵母膏和氧嗪酸钾联合喂养致高尿酸血症大鼠的血尿酸值,并且与阳性药组相比具有更轻的机体损伤,甚至能够减缓酵母膏和氧嗪酸钾联合喂养引发的大鼠肝肾组织病理损伤。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (10)
1.一种降尿酸药食同源组方,其特征在于,包括以下重量份的原料:薏苡仁15-30份、茯苓10-20份、车前草8-15份、山药10-20份、红花5-10份和葛根8-15份。
2.根据权利要求1所述的一种降尿酸药食同源组方,其特征在于,包括以下重量份的原料:薏苡仁30份、茯苓20份、车前草15份、山药20份、红花10份和葛根15份。
3.根据权利要求1所述的一种降尿酸药食同源组方,其特征在于,包括以下重量份的原料:薏苡仁20份、茯苓15份、车前草10份、山药15份、红花5份和葛根10份。
4.根据权利要求1所述的一种降尿酸药食同源组方,其特征在于,包括以下重量份的原料:薏苡仁15份、茯苓10份、车前草8份、山药10份、红花5份和葛根8份。
5.一种降尿酸药食同源组方的制备方法,其特征在于,具体包括以下步骤:
(1)按权利要求1-4任一项所述降尿酸药食同源组方的重量份数称取各原料;
(2)将各原料混合均匀,得到中药混合物;
(3)向中药混合物中加水,浸泡,回流,过滤,分别得到提取液A和药渣A;
(4)向药渣A中再次加水,回流,过滤,分别得到提取液B和药渣B;
(5)将提取液A和提取液B合并,得到混合提取液;
(6)将混合提取液浓缩,即得所述降尿酸药食同源组方;
或,向混合提取液中加入乙醇并搅拌,冷藏过夜,过滤,将上清液减压浓缩,即得所述降尿酸药食同源组方。
6.根据权利要求5所述的一种降尿酸药食同源组方的制备方法,其特征在于,步骤(3)中,所述水为蒸馏水,用量为中药混合物体积的6倍;所述浸泡的时间为30min;所述回流的状态为微沸,时间为50min。
7.根据权利要求5所述的一种降尿酸药食同源组方的制备方法,其特征在于,步骤(4)中,所述水为蒸馏水,用量为药渣A体积的4倍;所述回流的状态为微沸,时间为40min。
8.根据权利要求5所述的一种降尿酸药食同源组方的制备方法,其特征在于,步骤(6)中,所述浓缩至1g/mL。
9.根据权利要求5所述的一种降尿酸药食同源组方的制备方法,其特征在于,步骤(7)中,所述乙醇加入至醇浓度到达50%;所述减压浓缩的温度为70℃,真空度为(-0.09)-(-0.1)MPa。
10.一种如权利要求1-4任一项所述降尿酸药食同源组方或如权利要求5-9任一项所述制备方法制得的降尿酸药食同源组方在制备降尿酸或治疗由高蛋白饮食引发的肾功能损伤的药物或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310916640.6A CN116870110A (zh) | 2023-07-25 | 2023-07-25 | 一种降尿酸药食同源组方及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310916640.6A CN116870110A (zh) | 2023-07-25 | 2023-07-25 | 一种降尿酸药食同源组方及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116870110A true CN116870110A (zh) | 2023-10-13 |
Family
ID=88267850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310916640.6A Pending CN116870110A (zh) | 2023-07-25 | 2023-07-25 | 一种降尿酸药食同源组方及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116870110A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103100006A (zh) * | 2013-01-30 | 2013-05-15 | 无限极(中国)有限公司 | 一种具有降尿酸功能的中草药组合物 |
CN104940751A (zh) * | 2015-07-14 | 2015-09-30 | 无限极(中国)有限公司 | 一种组合物及其用途 |
CN109010655A (zh) * | 2018-10-22 | 2018-12-18 | 张玉峰 | 防治高尿酸血症的药食同源中药 |
CN112353909A (zh) * | 2020-12-10 | 2021-02-12 | 中国药科大学 | 预防和治疗痛风的中药组合物及其制备方法与应用 |
CN112603971A (zh) * | 2020-12-31 | 2021-04-06 | 广州白云山陈李济药厂有限公司 | 蛹虫草陈皮中药组合物、制备方法及其用途 |
CN114081123A (zh) * | 2020-08-24 | 2022-02-25 | 广东云药科技有限公司 | 一种用于痛风患者食用的营养粉配方 |
-
2023
- 2023-07-25 CN CN202310916640.6A patent/CN116870110A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103100006A (zh) * | 2013-01-30 | 2013-05-15 | 无限极(中国)有限公司 | 一种具有降尿酸功能的中草药组合物 |
CN104940751A (zh) * | 2015-07-14 | 2015-09-30 | 无限极(中国)有限公司 | 一种组合物及其用途 |
CN109010655A (zh) * | 2018-10-22 | 2018-12-18 | 张玉峰 | 防治高尿酸血症的药食同源中药 |
CN114081123A (zh) * | 2020-08-24 | 2022-02-25 | 广东云药科技有限公司 | 一种用于痛风患者食用的营养粉配方 |
CN112353909A (zh) * | 2020-12-10 | 2021-02-12 | 中国药科大学 | 预防和治疗痛风的中药组合物及其制备方法与应用 |
CN112603971A (zh) * | 2020-12-31 | 2021-04-06 | 广州白云山陈李济药厂有限公司 | 蛹虫草陈皮中药组合物、制备方法及其用途 |
Non-Patent Citations (1)
Title |
---|
郑曙琴等: "《于世家教授临证经验集》", vol. 1, 31 January 2022, 中国中医药出版社, pages: 150 - 151 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104435749B (zh) | 一种铁皮石斛复方制剂及其制备方法和应用 | |
CN102895320A (zh) | 一种防治高尿酸血症、痛风药食两用配方及制剂 | |
US10987396B2 (en) | Composition for improving internal circulation and delaying aging and application thereof | |
CN101332256B (zh) | 用于鸡传染性法氏囊炎的中药组合物及制备方法 | |
CN102048902B (zh) | 一种治疗肝炎的中药组合物、提取物及制备方法、应用和剂型 | |
CN108853433A (zh) | 一种治疗糖尿病肾病的中药及其制备方法 | |
CN100345566C (zh) | 一种用于减肥的药物组合物及其制备方法和用途 | |
CN102451276A (zh) | 一种治疗腹泻的中药方剂及制备方法 | |
CN104721467B (zh) | 一种治疗糖尿病肾病的中药组合物及其用途 | |
CN102293928A (zh) | 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用 | |
CN116870110A (zh) | 一种降尿酸药食同源组方及其制备方法与应用 | |
CN101693086B (zh) | 用于防治复发性口疮的中药复方制剂及其制备方法和应用 | |
CN113521221A (zh) | 一种君臣佐使配伍的黄精膏中药方剂 | |
CN102274428B (zh) | 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用 | |
CN101884760B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN102631492B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN112439030A (zh) | 一种快速降低尿酸的药物 | |
CN111110825A (zh) | 一种降高尿酸的组合物及其制备方法和应用 | |
CN111110719A (zh) | 具有降糖降压减肥排尿酸功能的中药及其生产方法 | |
CN115779046B (zh) | 一种防治糖尿病的中药组合物、中药制剂与应用 | |
CN105901736A (zh) | 含有青梅提取物的组合物在制备降尿酸保健品中的用途 | |
CN115944700B (zh) | 一种中药组合物及其制备方法和应用 | |
CN115607629B (zh) | 一种具有保肝解酒的中药组合物及其制备方法 | |
CN1176820A (zh) | 一种红参山楂保健酒 | |
CN106474380A (zh) | 具有护肝解酒功效的中药组合物、制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |